Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Invested Capital: 2010-2025

Historic Invested Capital for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $543.4 million.

  • Arrowhead Pharmaceuticals' Invested Capital rose 184.42% to $543.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $543.4 million, marking a year-over-year increase of 184.42%. This contributed to the annual value of $543.4 million for FY2025, which is 184.42% up from last year.
  • Arrowhead Pharmaceuticals' Invested Capital amounted to $543.4 million in Q3 2025, which was down 3.36% from $562.3 million recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Invested Capital peaked at $749.2 million during Q1 2025, and registered a low of $57.7 million during Q4 2024.
  • Its 3-year average for Invested Capital is $386.0 million, with a median of $382.0 million in 2023.
  • In the last 5 years, Arrowhead Pharmaceuticals' Invested Capital tumbled by 66.78% in 2024 and then surged by 184.42% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Invested Capital (Quarterly) stood at $372.6 million in 2021, then increased by 6.39% to $396.4 million in 2022, then slumped by 56.17% to $173.7 million in 2023, then slumped by 66.78% to $57.7 million in 2024, then skyrocketed by 184.42% to $543.4 million in 2025.
  • Its Invested Capital stands at $543.4 million for Q3 2025, versus $562.3 million for Q2 2025 and $749.2 million for Q1 2025.